Annual report pursuant to Section 13 and 15(d)

Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual)

v3.19.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2017
Jul. 01, 2018
Available-for-sale Securities, Total $ 38,200 $ 54,300   $ 54,300
Amortization of Intangible Assets, Total 58,715 47,076    
Other Assets, Noncurrent, Total 5,668 5,266    
Developed Technology Rights [Member] | Cost of Sales [Member]        
Amortization of Intangible Assets, Total 33,300 25,300 $ 23,100  
Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] | Selling, General and Administrative Expenses [Member]        
Amortization of Intangible Assets, Total 25,400 21,600 $ 21,300  
Other Noncurrent Assets [Member]        
Inventory, Finished Goods, Net of Reserves, Non-current 3,239      
ChemoCentryx, Inc (CCXI) [Member]        
Available-for-sale Securities, Gross Realized Gain (Loss), Total (16,100)      
Available-for-sale Equity Securities, Amortized Cost Basis, Total $ 18,800 $ 18,800    
ChemoCentryx, Inc (CCXI) [Member]        
Share Price $ 9.30 $ 13.17